Business Monitor International


Austria Pharmaceuticals & Healthcare Report

Published 19 May 2014

  • 67 pages
 
$1,295.00
Austria Pharmaceuticals & Healthcare Report

BMI View : Austria's economy is set to grow at a faster clip in the second half of 2014 and domestic consumer demand is poised to strengthen in this period. We have revised the healthcare and pharmaceutical market forecast slightly upwards to reflect this. The EUR-USD exchange rate continues to provide investment opportunities for overseas investors. In the medium term, Austria's pharmaceutical and healthcare spending will post weak growth as the government caps growth in public healthcare expenditure to 3.6% until 2016. The focus will be on seeking efficiency savings in healthcare delivery and pharmaceutical expenditure s .

Headline Expenditure Projections

  • Pharmaceuticals: EUR4.58bn (US$6.09bn) in 2013 to EUR4.73bn (US$6.0bn) in 2014; +3.2% in local currency terms and -1.5% in US dollar terms.

  • Healthcare: EUR33.5bn (US$44.5bn) in 2013 to EUR34.4bn (US$43.6bn) in 2014; +2.7% in local currency terms and -2.0% in US dollar terms.

Risk/Reward Rating

Based on the inherent Rewards and Risks for drugmakers operating in the country, Austria has been assigned an RRR score of 70.3, making it the fifth most attractive market out of the 15 pharmaceutical markets in Western Europe. Last quarter, Austria was the third most attractive market, but this change in ranks is due to a stabilising of markets across wider Europe rather than worsening conditions in Austria. Indeed, we expect economic recovery to gain traction in the second half of 2014 and with its high per capita healthcare spending and ageing population, Austria remains one of the more attractive markets in the region.

Key Trends & Developments

  • According to the budget for 2014, Austria's healthcare expenditure is to be aligned with the GDP growth rate by 2016 and healthcare expenditure will be stabilised at 7% of the GDP by 2020. As part of the healthcare reform bill 2013, the annual growth of public healthcare expenditure will be reduced to 3.6% until 2016. Thereafter, the annual growth will be capped at the...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2010-2018)
14
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
17
Prescription Drug Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
21
Austria
22
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
23
OTC Medicine Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
25
Macroeconomic Forecasts
26
Economic Analysis
26
Table: Austria - Economic Activity
30
Industry Risk Reward Ratings
31
Western Europe Risk/Reward Ratings
31
Austria Risk/Reward Ratings
36
Rewards
36
Risks
37
Market Overview
38
Industry Trends And Developments
40
Epidemiology
40
Regulatory Development
42
Competitive Landscape
47
Pharmaceutical Distribution
49
Pharmaceutical Wholesale
49
Table: Members Of ARGE Pharmazeutika, 2011
50
Pharmaceutical Retail
51
Table: Pharmacy Outlets by Type, 2005-2009
52
Table: Pharmacy Outlets by State, 2005-2009
52
Demographic Forecast
54
Table: Austria's Population By Age Group, 1990-2020 ('000)
55
Table: Austria's population By Age Group, 1990-2020 (% of total)
56
Table: Austria's Key Population Ratios, 1990-2020
57
Table: Austria's Rural And Urban Population, 1990-2020
57
Glossary
58
Methodology
60
Pharmaceutical Expenditure Forecast Model
60
Healthcare Expenditure Forecast Model
60
Notes On Methodology
61
Risk/Reward Ratings Methodology
62
Ratings Overview
63
Table: Pharmaceutical Risk/Reward Ratings Indicators
63
Indicator Weightings
64

The Austria Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Austria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Austrian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Austria to test other views - a key input for successful budgeting and strategic business planning in the Austrian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Austrian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Austria.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%